BioNTech Valuation
Is 22UA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 22UA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 22UA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 22UA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 22UA?
Key metric: As 22UA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 22UA's PS Ratio? | |
|---|---|
| PS Ratio | 8.6x |
| Sales | €3.04b |
| Market Cap | €26.05b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.8x |
| Enterprise Value/EBITDA | -30.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 22UA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14x | ||
MOLN Molecular Partners | 29.8x | 57.8% | CHF 178.8m |
BSLN Basilea Pharmaceutica | 3.4x | 6.0% | CHF 500.6m |
KURN Kuros Biosciences | 17.4x | n/a | CHF 913.0m |
GALD Galderma Group | 5.4x | 11.6% | CHF 20.8b |
22UA BioNTech | 8.6x | 3.4% | CHF 27.1b |
Price-To-Sales vs Peers: 22UA is good value based on its Price-To-Sales Ratio (8.6x) compared to the peer average (14x).
Price to Sales Ratio vs Industry
How does 22UA's PS Ratio compare vs other companies in the European Biotechs Industry?
| 38 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 38 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 22UA is expensive based on its Price-To-Sales Ratio (8.6x) compared to the European Biotechs industry average (8.1x).
Price to Sales Ratio vs Fair Ratio
What is 22UA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.6x |
| Fair PS Ratio | 5.9x |
Price-To-Sales vs Fair Ratio: 22UA is expensive based on its Price-To-Sales Ratio (8.6x) compared to the estimated Fair Price-To-Sales Ratio (5.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CHF 94.64 | CHF 120.45 +27.3% | 9.5% | CHF 151.12 | CHF 106.49 | n/a | 18 |
| Nov ’25 | n/a | CHF 112.35 0% | 17.1% | CHF 148.58 | CHF 77.67 | n/a | 18 |
| Oct ’25 | CHF 101.13 | CHF 104.90 +3.7% | 19.6% | CHF 144.68 | CHF 71.91 | n/a | 18 |
| Sep ’25 | CHF 74.97 | CHF 93.38 +24.5% | 20.4% | CHF 146.44 | CHF 72.79 | n/a | 18 |
| Aug ’25 | CHF 76.19 | CHF 97.51 +28.0% | 20.3% | CHF 149.47 | CHF 78.74 | n/a | 18 |
| Jul ’25 | CHF 73.23 | CHF 99.23 +35.5% | 20.2% | CHF 152.93 | CHF 80.05 | n/a | 18 |
| Jun ’25 | CHF 90.34 | CHF 100.88 +11.7% | 20.4% | CHF 155.28 | CHF 81.46 | n/a | 18 |
| May ’25 | CHF 80.78 | CHF 104.37 +29.2% | 20.7% | CHF 154.20 | CHF 81.51 | n/a | 18 |
| Apr ’25 | n/a | CHF 105.78 0% | 23.6% | CHF 168.60 | CHF 81.03 | n/a | 18 |
| Mar ’25 | CHF 78.97 | CHF 111.20 +40.8% | 22.5% | CHF 165.26 | CHF 86.95 | n/a | 17 |
| Feb ’25 | CHF 82.57 | CHF 109.46 +32.6% | 22.4% | CHF 161.50 | CHF 84.97 | n/a | 16 |
| Jan ’25 | n/a | CHF 113.39 0% | 21.0% | CHF 158.94 | CHF 85.88 | n/a | 16 |
| Dec ’24 | CHF 87.65 | CHF 117.09 +33.6% | 23.0% | CHF 172.94 | CHF 86.18 | n/a | 17 |
| Nov ’24 | n/a | CHF 126.54 0% | 23.1% | CHF 175.48 | CHF 92.43 | n/a | 17 |
| Oct ’24 | n/a | CHF 133.80 0% | 22.9% | CHF 180.14 | CHF 90.81 | CHF 101.13 | 16 |
| Sep ’24 | n/a | CHF 136.90 0% | 26.1% | CHF 218.68 | CHF 87.10 | CHF 74.97 | 17 |
| Aug ’24 | n/a | CHF 141.05 0% | 24.7% | CHF 218.68 | CHF 94.81 | CHF 76.19 | 17 |
| Jul ’24 | n/a | CHF 148.65 0% | 23.1% | CHF 223.32 | CHF 96.82 | CHF 73.23 | 16 |
| Jun ’24 | n/a | CHF 146.01 0% | 23.4% | CHF 222.46 | CHF 96.45 | CHF 90.34 | 17 |
| May ’24 | n/a | CHF 159.77 0% | 23.7% | CHF 235.98 | CHF 114.71 | CHF 80.78 | 17 |
| Apr ’24 | n/a | CHF 168.27 0% | 22.2% | CHF 238.15 | CHF 119.64 | n/a | 16 |
| Mar ’24 | n/a | CHF 191.64 0% | 23.4% | CHF 276.48 | CHF 131.37 | CHF 78.97 | 15 |
| Feb ’24 | n/a | CHF 192.61 0% | 23.5% | CHF 278.08 | CHF 132.58 | CHF 82.57 | 15 |
| Jan ’24 | n/a | CHF 198.61 0% | 23.2% | CHF 305.53 | CHF 141.84 | n/a | 15 |
| Dec ’23 | n/a | CHF 200.71 0% | 22.4% | CHF 304.11 | CHF 141.90 | CHF 87.65 | 16 |
| Nov ’23 | n/a | CHF 209.75 0% | 24.6% | CHF 314.44 | CHF 132.03 | n/a | 16 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Gerresheimer
€2.6b
Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.
GXI
€75.60
7D
0%
1Y
0%
Roche Holding
CHF 204.3b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.
ROG
CHF 254.30
7D
-0.6%
1Y
6.5%
Bristol-Myers Squibb
US$100.3b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMY
US$54.24
7D
0%
1Y
0%